For the first six months of 2023, Equasens has reported an 11.4% increase in net income (group share) to 22 million euros and a 6.9% rise in operating income before non-recurring items to 27.5 million, on sales up 8.7% to 112.6 million.

For its main division, Pharmagest, the healthcare IT specialist reported a 9.5% increase in operating profit to 18.4 million, "driven by its new mobile and backup software solutions, and by a sharp rise in recurring sales".

Looking forward to the second half of 2023 "with confidence", Equasens is maintaining its growth forecasts for 2023 at this stage, excluding exceptional events. The integration of recent acquisitions will be its priority over the coming months.

Copyright (c) 2023 CercleFinance.com. All rights reserved.